Pulmonary Embolism

Categories: Blood diseases, Cardiovascular diseases, Respiratory diseases

Aliases & Classifications for Pulmonary Embolism

MalaCards integrated aliases for Pulmonary Embolism:

Name: Pulmonary Embolism 12 29 54 6 42 43 15 62 17 71 32
Pulmonary Artery Embolism 12
Pulmonary Embolus 12
Pulmonary Emboli 15


External Ids:

Disease Ontology 12 DOID:9477
MeSH 43 D011655
NCIt 49 C50713
SNOMED-CT 67 59282003
ICD10 32 I26 I26.0 I26.9
UMLS 71 C0034065

Summaries for Pulmonary Embolism

MedlinePlus : 42 What is a pulmonary embolism (PE)? A pulmonary embolism (PE) is a sudden blockage in a lung artery. It usually happens when a blood clot breaks loose and travels through the bloodstream to the lungs. PE is a serious condition that can cause Permanent damage to the lungs Low oxygen levels in your blood Damage to other organs in your body from not getting enough oxygen PE can be life-threatening, especially if a clot is large, or if there are many clots. What causes a pulmonary embolism (PE)? The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung. Who is at risk for a pulmonary embolism (PE)? Anyone can get a pulmonary embolism (PE), but certain things can raise your risk of PE: Having surgery, especially joint replacement surgery Certain medical conditions, including Cancers Heart diseases Lung diseases A broken hip or leg bone or other trauma Hormone-based medicines, such as birth control pills or hormone replacement therapy Pregnancy and childbirth. The risk is highest for about six weeks after childbirth. Not moving for long periods, such as being on bed rest, having a cast, or taking a long plane flight Age. Your risk increases as you get older, especially after age 40. Family history and genetics. Certain genetic changes that can increase your risk of blood clots and PE. Obesity What are the symptoms of a pulmonary embolism (PE)? Half the people who have pulmonary embolism have no symptoms. If you do have symptoms, they can include shortness of breath, chest pain or coughing up blood. Symptoms of a blood clot include warmth, swelling, pain, tenderness and redness of the leg. How is a pulmonary embolism (PE) diagnosed? It can be difficult to diagnose PE. To make a diagnosis, your health care provider will Take your medical history, including asking about your symptoms and risk factors for PE Do a physical exam Run some tests, including various imaging tests and possibly some blood tests What are the treatments for a pulmonary embolism (PE)? If you have PE, you need medical treatment right away. The goal of treatment is to break up clots and help keep other clots from forming. Treatment options include medicines and procedures. Medicines Anticoagulants, or blood thinners, keep blood clots from getting larger and stop new clots from forming. You might get them as an injection, a pill, or through an I.V. (intravenous). They can cause bleeding, especially if you are taking other medicines that also thin your blood, such as aspirin. Thrombolytics are medicines to dissolve blood clots. You may get them if you have large clots that cause severe symptoms or other serious complications. Thrombolytics can cause sudden bleeding, so they are used if your PE is serious and may be life-threatening. Procedures Catheter-assisted thrombus removal uses a flexible tube to reach a blood clot in your lung. Your health care provider can insert a tool in the tube to break up the clot or to deliver medicine through the tube. Usually you will get medicine to put you to sleep for this procedure. A vena cava filter may be used in some people who cannot take blood thinners. Your health care provider inserts a filter inside a large vein called the vena cava. The filter catches blood clots before they travel to the lungs, which prevents pulmonary embolism. But the filter does not stop new blood clots from forming. Can pulmonary embolism (PE) be prevented? Preventing new blood clots can prevent PE. Prevention may include Continuing to take blood thinners. It's also important to get regular checkups with your provider, to make sure that the dosage of your medicines is working to prevent blood clots but not causing bleeding. Heart-healthy lifestyle changes, such as heart-healthy eating, exercise, and, if you smoke, quitting smoking Using compression stockings to prevent deep vein thrombosis (DVT) Moving your legs when sitting for long periods of time (such as on long trips) Moving around as soon as possible after surgery or being confined to a bed NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Pulmonary Embolism, also known as pulmonary artery embolism, is related to puerperal pulmonary embolism and chronic thromboembolic pulmonary hypertension, and has symptoms including hemoptysis, snoring and coughing. An important gene associated with Pulmonary Embolism is PLAT (Plasminogen Activator, Tissue Type), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Phenprocoumon and Furosemide have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 An artery disease characterized by a blockage of the main artery of the lung or one of its branches by a substance that has travelled from elsewhere in the body, e.g. a blood clot.

PubMed Health : 62 About pulmonary embolism: Pulmonary embolism (PULL-mun-ary EM-bo-lizm), or PE, is a sudden blockage in a lung artery. The blockage usually is caused by a blood clot that travels to the lung from a vein in the leg. A clot that forms in one part of the body and travels in the bloodstream to another part of the body is called an embolus (EM-bo-lus). PE is a serious condition that can:

Wikipedia : 74 Pulmonary embolism (PE) is a blockage of an artery in the lungs by a substance that has moved from... more...

Related Diseases for Pulmonary Embolism

Diseases related to Pulmonary Embolism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1139)
# Related Disease Score Top Affiliating Genes
1 puerperal pulmonary embolism 34.0 SERPINC1 F10 APOH
2 chronic thromboembolic pulmonary hypertension 33.8 NPPB CRP
3 prothrombin-related thrombophilia 33.6 MTHFR F2 F13A1
4 pleural disease 33.2 F2 CRP ALB
5 respiratory failure 33.1 NPPB F3 F2 CRP ALB
6 protein c deficiency 32.9 SERPINE1 SERPINC1 MTHFR F9 F5 F2
7 essential thrombocythemia 32.8 VWF SERPINE1 SERPINC1 MTHFR F3 F2
8 antithrombin iii deficiency 32.4 SERPINC1 MTHFR F5 F3 F2 F10
9 cardiogenic shock 32.1 PLAT NPPB CRP
10 cardiac arrest 32.0 TNNT2 NPPB FABP3 ALB
11 thrombophilia due to thrombin defect 32.0 SERPINE1 SERPINC1 PLAT MTHFR F5 F3
12 vascular disease 32.0 VWF SERPINE1 SERPINC1 PLAT NPPB MTHFR
13 protein s deficiency 32.0 SERPINE1 SERPINC1 MTHFR F5 F3 F2
14 acute cor pulmonale 31.8 PLAT NPPB F3
15 pulmonary hypertension 31.6 VWF SERPINE1 SERPINC1 PLAT NPPB F3
16 pneumonia 31.5 F3 F2 CRP ALB
17 hemopericardium 31.5 TNNI3 F3 F2
18 varicose veins 31.4 VWF SERPINC1 PLAT MTHFR F5 F2
19 tricuspid valve insufficiency 31.3 TNNI3 NPPB F3 F2 CRP ALB
20 sleep apnea 31.3 SERPINE1 NPPB CRP ALB
21 congestive heart failure 31.3 TNNT2 TNNI3 NPPB FABP3 CRP ALB
22 pulmonary edema 31.3 TNNT2 TNNI3 SERPINC1 NPPB F2 CRP
23 inferior myocardial infarction 31.2 TNNI3 PLAT NPPB
24 endocarditis 31.1 TNNI3 SERPINE1 SERPINC1 PLAT F2 CRP
25 infective endocarditis 31.1 TNNT2 TNNI3 SERPINE1 F2 CRP APOH
26 thrombophilia due to activated protein c resistance 31.1 VWF SERPINF2 SERPINE1 SERPINC1 PLAT MTHFR
27 pericardial effusion 31.1 TNNI3 NPPB F3 F2 CRP ALB
28 post-thrombotic syndrome 31.0 SERPINE1 SERPINC1 PLAT F5 F3 F2
29 pericarditis 31.0 TNNT2 TNNI3 NPPB CRP ALB
30 may-thurner syndrome 31.0 F5 APOH
31 acute pulmonary heart disease 31.0 PLAT NPPB F3
32 atrial standstill 1 31.0 TNNT2 TNNI3 NPPB
33 toxic shock syndrome 31.0 SERPINC1 F3 CRP
34 pleural empyema 31.0 F2 CRP ALB
35 left bundle branch hemiblock 30.9 TNNT2 TNNI3 NPPB CRP
36 angina pectoris 30.9 TNNI3 PLAT NPPB F3 CRP
37 compartment syndrome 30.9 SERPINC1 F3 F2 CRP ALB
38 chronic venous insufficiency 30.9 SERPINE1 PLAT F2 CRP
39 heparin-induced thrombocytopenia 30.9 SERPINC1 F3 F10
40 patent ductus arteriosus 1 30.9 NPPB CRP ALB
41 lemierre's syndrome 30.9 SERPINC1 MTHFR F3 F2 CRP
42 venous insufficiency 30.9 VWF SERPINE1 PLAT MTHFR F5 F2
43 intracranial embolism 30.8 SERPINC1 PLAT F3 F2 CRP ALB
44 esophageal varix 30.8 SERPINC1 F3 F2 ALB
45 kidney disease 30.8 SERPINE1 NPPB MTHFR F3 CRP ALB
46 thoracic outlet syndrome 30.8 SERPINC1 PLAT F2
47 sticky platelet syndrome 30.8 SERPINE1 SERPINC1 F5
48 anuria 30.8 F3 F2 CRP ALB
49 acute cystitis 30.7 F2 CRP ALB
50 portal hypertension 30.7 VWF F3 F2 ALB

Graphical network of the top 20 diseases related to Pulmonary Embolism:

Diseases related to Pulmonary Embolism

Symptoms & Phenotypes for Pulmonary Embolism

UMLS symptoms related to Pulmonary Embolism:

hemoptysis, snoring, coughing

MGI Mouse Phenotypes related to Pulmonary Embolism:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.16 ALB CRP F10 F13A1 F2 F3
2 homeostasis/metabolism MP:0005376 10.11 ALB APOH CRP F10 F13A1 F2
3 mortality/aging MP:0010768 9.55 ALB APOH F10 F13A1 F2 F3
4 liver/biliary system MP:0005370 9.5 ALB F5 F9 FABP3 MTHFR SERPINC1

Drugs & Therapeutics for Pulmonary Embolism

PubMed Health treatment related to Pulmonary Embolism: 62

Pulmonary embolism (PE) is treated with medicines, procedures, and other therapies . The main goals of treating PE are to stop the blood clot from getting bigger and keep new clots from forming. Treatment may include medicines to thin the blood and slow its ability to clot. If your symptoms are life threatening, your doctor may give you medicine to quickly dissolve the clot. Rarely, your doctor may use surgery or another procedure to remove the clot.

Drugs for Pulmonary Embolism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 365)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Phenprocoumon Approved, Investigational Phase 4 435-97-2 54680692 9908
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
Dalteparin Approved Phase 4 9005-49-6
Phylloquinone Approved, Investigational Phase 4 84-80-0
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
Streptokinase Approved, Investigational Phase 4 9002-01-1
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
Pancrelipase Approved, Investigational Phase 4 53608-75-6
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
15 fluindione Approved, Investigational Phase 4 957-56-2
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
Ibuprofen Approved Phase 4 15687-27-1 3672
Phenindione Approved, Investigational Phase 4 83-12-5 4760
Dobutamine Approved Phase 4 34368-04-2 36811
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Edoxaban Approved Phase 4 480449-70-5
Nadroparin Approved, Investigational Phase 4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
27 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Betrixaban Approved, Investigational Phase 4 330942-05-7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Enoxaparin Approved Phase 4 9005-49-6 772
Apixaban Approved Phase 4 503612-47-3 10182969
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Racepinephrine Approved Phase 4 329-65-7 838
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
46 Monteplase Investigational Phase 4 156616-23-8
47 Menaquinone Investigational Phase 4 1182-68-9
48 Tezosentan Investigational Phase 4 180384-57-0
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
Coumarin Experimental Phase 4 91-64-5 323

Interventional clinical trials:

(show top 50) (show all 1036)
# Name Status NCT ID Phase Drugs
1 Cooperative Investigation Plan for Home Treatment of Pulmonary Embolism Unknown status NCT00214929 Phase 4
2 A Safety and Efficacy Study for Implantation and Retrieval Procedures Using the VENATECH® Retrieval Filter System Unknown status NCT02674672 Phase 4
3 Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism: AYKAN Trial Unknown status NCT02029456 Phase 4 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
4 A Prospective Randomised Controlled Study to Evaluate Outcomes of the Treatment With Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism Undergoing Endovascular Mechanical Fragmentation and Thrombolytic Therapy Unknown status NCT02979561 Phase 4 Dabigatran Etexilate;Warfarin
5 Low Dose Rt-PA Plus LMWH Compared With LMWH Alone for the Treatment of Normotensive Pulmonary Embolism Patients With Acute RV Dysfunction: A Randomized,Multi-Center,Controlled Trial Unknown status NCT01531829 Phase 4 Recombinant tissue plasminogen activator (rt-PA);Low Molecular Weight Heparin
6 Comparing a Diuretic Vascular Filling in the Initial Management of Acute Pulmonary Embolism With Right Ventricular Dysfunction Normotensive Unknown status NCT02531581 Phase 4 Furosemide;NaCl 9% isotonic
7 Gadolinium Enhanced Dual-Energy Computed Tomography: A Feasibility Study to Assess Image Quality and Diagnostic Confidence Unknown status NCT02163005 Phase 4 Gadolinium
8 A Feasibility Study to Explore the Difference in Healing Time Between Teriparatide Treatment and Standard Care on Weber B Ankle Fractures in Older People Unknown status NCT02955056 Phase 4 Forsteo
9 Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER) Unknown status NCT01252420 Phase 4 Enoxaparin
10 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
11 Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis Unknown status NCT02959801 Phase 4
12 Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting Unknown status NCT00776633 Phase 4 aspirin;clopidogrel;oral anticoagulation
13 The Treatment Effect of Inhaled Corticosteroid and Long-acting beta2 Agonist Combination Versus Long-acting Anti-cholinergic Agent on Stratified COPD Patients Based on the Levels of Exhaled Nitric Oxide Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
14 Effect of Intravenous Tranexamic Acid on Reduction of Blood Losses in Hip Fracture Patients. A Randomized, Controlled, Double-blind Study Unknown status NCT03211286 Phase 4 Tranexamic Acid;Saline Solution
15 Comparison of Combined Topical Tranexamic Acid With Floseal® With Intravenous Tranexamic Acid on Blood Loss in Total Knee Arthroplasty Unknown status NCT03328832 Phase 4 Topical tranexamic acid;Floseal®;rivaroxaban (10mg)
16 Reducing Blood Loss During Total Knee Arthroplasty Using Tisseel: A Prospective Randomized Control Trial Unknown status NCT03310060 Phase 4 Tisseel;Tranexamic Acid
17 Residual Vein Thrombosis Establishes the Optimal Duration of Low Molecular Weight Heparins in Cancer Patients With Deep Vein Thrombosis of the Lower Limbs Unknown status NCT00450645 Phase 4 low molecular weight heparin
18 Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism Unknown status NCT01956955 Phase 4 enoxaparin ,alteplase, unfractionated heparin
19 Comparison of Topical Tranexamic Acid and Floseal® on Blood Loss After Total Knee Arthroplasty in Patients With a Thromboembolic Risk Unknown status NCT02865174 Phase 4 Topical tranexamic acid;Floseal®;Enoxaparin
20 Prospective Randomized Study Comparing Topical Versus Intravenous Tranexamic Acid in Anterior Total Hip Arthroplasty Unknown status NCT03359525 Phase 4 Tranexamic Acid
21 Pharmacokinetic/Pharmacodynamic Study of Monteplase ("Cleactor") in Acute Pulmonary Embolism Completed NCT00442234 Phase 4 Monteplase
22 Detection of Pulmonary Embolism Comparing Isovue-370 and Visipaque 320 Using 64-Slice Multi-Detector Computed Tomographic Angiography Completed NCT00351754 Phase 4 Isovue
23 The Cordis Protection From Pulmonary Embolism With the Permanent OptEase™ Filter - A Post Marketing Surveillance Study (PROOF Study) Completed NCT00233740 Phase 4
24 Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism in Context of Pulmonary Hypertension, Right Heart Failure and Patient Functional Ability Completed NCT02132689 Phase 4 Actilyse (Thrombolytic therapy);Heparine (Standard anticoagulation therapy)
25 A Non-Randomized Prospective Study of IVC Filter Retrieval Completed NCT00196118 Phase 4
26 N-acetylcysteine, Sodium Bicarbonate and Normal Saline Alone Prophylaxis for Spiral Computed Tomography Pulmonary Angiography in the Emergency Department on Suspicion of Pulmonary Emboli: A Randomized Controlled Trial Completed NCT02483143 Phase 4 NAC;NaHCO3;Normal Saline
27 Long Term Subcutaneous Tinzaparin Compared With Tinzaparin and Oral Anticoagulants in the Treatment of the Acute Pulmonary Embolism Completed NCT00711308 Phase 4 tinzaparin;acenocoumarol
28 Clinical Trial of Two Durations of Warfarin Therapy in the Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism Completed NCT00365950 Phase 4 Duration of anticoagulation;Warfarin duration
29 PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study Completed NCT00457158 Phase 4
30 MulticEnter Trial of Rivaroxaban for Early disCharge of pUlmonaRY Embolism From the Emergency Department Completed NCT02584660 Phase 4 Rivaroxaban;Standard-of-care
31 Effects of Intravenous Epoprostenol Sodium (Flolan®) in Patients With Moderate-to-Severe Pulmonary Thrombo-Embolism Completed NCT01014156 Phase 4 epoprostenol
32 Warfarin Dosing: Pharmacogenetic Algorithm Compared to Pharmacist's Dosing Completed NCT00511173 Phase 4
33 Age-adjusted D-dimer Cut-off Levels to Rule Out Pulmonary Embolism: a Prospective Outcome Study. Completed NCT01134068 Phase 4
34 Efficacy and Safety Evaluation of Recombinant Streptokinase and Urokinase in the Treatment of Pulmonary Embolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00968929 Phase 4 Recombinant Streptokinase;Urokinase
35 Chemoprophylaxis Plus Early Ambulation Prevent Chinese Thoracic Surgery Patients From Pulmonary Embolism Completed NCT03862755 Phase 4 Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)
36 D-dimer Test to Establish Duration of Anticoagulation After a First Idiopathic Episode of Venous Thromboembolism; the Prospective Randomized "Prolong" Study Completed NCT00264277 Phase 4 Vitamin K antagonist (Coumarin anticoagulants)
37 Venous Thromboembolic Prophylaxis After Major Trauma: A Randomized Controlled Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Completed NCT01729559 Phase 4 5000 Units unfractionated Heparin Q 8 hr;30mg enoxaparin Q12 hr
38 Objective Assessment of Pulmonary Embolism Can be Deferred Without Increased Risk Completed NCT00381511 Phase 4 low molecular weight heparin
39 Prospective Randomized Trial of a Clinical Algorithm to Predict the Loading Dose of Phenprocoumon Completed NCT00586287 Phase 4 Phenprocoumon
40 Does Anticoagulant Control Change Following Referral Back to the Primary Care Physician? A Prospective Randomized Trial Completed NCT00735189 Phase 4
41 Prospective, Multicenter Study Investigating Efficacy and Safety of Oral Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism in Korean Patients With Cancers Completed NCT01989845 Phase 4 Rivaroxaban
42 Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid Completed NCT00603317 Phase 4 Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo;Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid
43 Efficacy of Tranexamic Acid in Reducing Perioperative Bleeding in Patients Undergoing Radical Prostatectomy. A Randomized Controlled Double-blind Study. Completed NCT00670345 Phase 4 Tranexamic Acid;Placebo
44 Mepivacaine vs. Bupivacaine Spinal Anesthetic in Total Knee Arthroplasty, a Randomized Controlled Clinical Trial Completed NCT02980926 Phase 4 Mepivacaine;Bupivacaine
45 Efficacy and Safety Evaluation of 12-h and 2-h Urokinase Regimes in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00799968 Phase 4 Urokinase;Urokinase
46 Efficacy and Safety of Body Weight Adjusted Nadroparin vs Standard Unfractionated Heparin for the Initial Treatment of Pulmonary Thromboembolism:a Multi-Centre, Randomised Controlled Trial in China Completed NCT00796692 Phase 4 Nadroparin;Unfractionated heparin(UFH)
47 Efficacy and Safety Evaluation of Low Dosage of Recombinant Tissue Plasminogen Activator (rt-PA) in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00781378 Phase 4 rt-PA;rt-PA
48 Cystic Fibrosis and Totally Implantable Vascular Access Devices: Evaluation of the Incidence of Venous Thrombosis Related to the Catheter and Study of the Genetic and Acquired Risk Factors Completed NCT00244270 Phase 4
49 Dose-dependent Drug-drug Interaction Between Paracetamol and Warfarin in Adults Receiving Long-term Oral Anticoagulants: A Randomized Controlled Trial Completed NCT01104337 Phase 4 paracetamol;paracetamol;Placebo
50 Treatment of Upper Extremity Deep-Vein Thrombosis Completed NCT00245856 Phase 4 Dalteparin sodium injection;Warfarin

Search NIH Clinical Center for Pulmonary Embolism

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Dalteparin Sodium
Danaparoid sodium
heparin calcium
heparin sodium
heparin sodium, bovine
heparin sodium, porcine
Papaverine Hydrochloride
Tinzaparin sodium
Warfarin Sodium

Cochrane evidence based reviews: pulmonary embolism

Genetic Tests for Pulmonary Embolism

Genetic tests related to Pulmonary Embolism:

# Genetic test Affiliating Genes
1 Pulmonary Embolism (disease) 29

Anatomical Context for Pulmonary Embolism

MalaCards organs/tissues related to Pulmonary Embolism:

Lung, Heart, Testes, Liver, Brain, Breast, Bone

Publications for Pulmonary Embolism

Articles related to Pulmonary Embolism:

(show top 50) (show all 31862)
# Title Authors PMID Year
Pulmonary Vascular Disease Evaluation with Magnetic Resonance Angiography. 42 61
32471539 2020
Comparison of international societal guidelines for the diagnosis of suspected pulmonary embolism during pregnancy. 61 42
32109405 2020
Catheter directed interventions for pulmonary embolism: current status and future prospects. 61 42
31937150 2020
Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox. 54 61
20513806 2010
Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. 54 61
20007142 2010
Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. 54 61
20447541 2010
Clinical usefulness of prothrombin fragment 1+2 in patients with suspected pulmonary embolism. 54 61
19394681 2010
Etanercept and venous thromboembolism: a case series. 61 54
20157435 2010
A serious drug interaction leading to spontaneous total hyphema. 61 54
20393256 2010
[High-risk factors and clinical pathological analysis in 21 cases of fatal pulmonary embolism]. 54 61
20019774 2009
Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis. 54 61
19525265 2009
Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome. 61 54
20040816 2009
Thrombophilia-related genetic variations in patients with pulmonary embolism in the main teaching hospital in Jordan. 54 61
19618008 2009
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. 54 61
19247590 2009
Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. 54 61
19087222 2009
N-terminal pro-B-type natriuretic peptide predicts the burden of pulmonary embolism. 54 61
19214022 2009
Thrombo-embolic occlusion of the left anterior descending coronary artery complicating left atrial radiofrequency ablation. 61 54
18988653 2009
B-type natriuretic peptide in acute pulmonary embolism. 61 54
18706401 2008
Natriuretic peptides in acute pulmonary embolism: a systematic review. 61 54
18626627 2008
[Heparin-induced thrombocythopenia in a patient with massive pulmonary embolism and dilated cardiomyopathy, successfuly treated with fondaparinux - a case report]. 61 54
19169978 2008
[Massive pulmonary embolism]. 54 61
18775637 2008
Mechanisms of the factor V Leiden paradox. 54 61
18617648 2008
[Oral contraceptives use increases venous thromboembolic risk even for minor surgical procedure - a case report]. 54 61
19006032 2008
Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism. 54 61
18664972 2008
Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. 54 61
18556626 2008
B-type natriuretic peptide as an indicator of right ventricular dysfunction in acute pulmonary embolism. 54 61
17537186 2008
Comparison of 8 biomarkers for prediction of right ventricular hypokinesis 6 months after submassive pulmonary embolism. 61 54
18657661 2008
[Massive pulmonary embolism treated with a reduced dose of alteplase in a patient with acute renal failure]. 54 61
18803142 2008
Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. 61 54
18495689 2008
Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. 54 61
18256058 2008
Mycoplasma pneumonia and pulmonary embolism in a child due to acquired prothrombotic factors. 61 54
18041082 2008
Epidural hematoma following tissue plasminogen activator (tPA) therapy for pulmonary embolism in a pediatric patient with stage IV Burkitt's lymphoma: a case report. 54 61
17854866 2008
[The efficacy of alteplase in pulmonary embolism treatment]. 61 54
18833155 2008
Prognostic value of brain natriuretic peptide in acute pulmonary embolism. 61 54
18721456 2008
Correlation between cardiac biomarkers and right ventricular enlargement on chest CT in non massive pulmonary embolism. 54 61
17716710 2008
HyBeacon probes for rapid DNA sequence detection and allele discrimination. 61 54
18695966 2008
Recurrent thrombembolic risk in patients with multiple thrombophilic disorders. 54 61
19366087 2008
Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. 61 54
18158473 2008
Persistent NT-proBNP elevation in acute pulmonary embolism predicts early death. 61 54
17507005 2007
Paradoxical embolus illustrating speed of action of recombinant tissue plasminogen activator in massive pulmonary embolism. 54 61
17513552 2007
Tenecteplase to treat pulmonary embolism in the emergency department. 54 61
17221330 2007
Combined utility of brain natriuretic peptide and cardiac troponin T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism. 54 61
16814410 2007
Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. 61 54
17345160 2007
Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients. 61 54
17145624 2007
Spotlight on reteplase in thrombotic occlusive disorders. 54 61
17263591 2007
Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. 61 54
17127709 2007
[Value of plasma BNP levels as a prognostic marker in lung and heart disorders]. 61 54
17978918 2007
Heart-type fatty acid-binding proteins (H-FABP): a reliable tool for initial risk stratification of pulmonary embolism? 61 54
17208938 2007
Massive pulmonary embolism secondary to anticardiolipin antibody syndrome. 61 54
17256569 2007
Evaluation of B-type natriuretic peptide to predict complicated pulmonary embolism in patients aged 65 years and older: brief report. 54 61
16938601 2006

Variations for Pulmonary Embolism

ClinVar genetic disease variations for Pulmonary Embolism:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PLAT NM_000930.5(PLAT):c.826C>T (p.Pro276Ser)SNV Uncertain significance 627396 8:42039518-42039518 8:42182000-42182000

Expression for Pulmonary Embolism

Search GEO for disease gene expression data for Pulmonary Embolism.

Pathways for Pulmonary Embolism

Pathways related to Pulmonary Embolism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
12.58 SERPINC1 FGB F9 F5 F3 F2
Show member pathways
Show member pathways
Show member pathways
11.64 VWF FGB F2
6 11.61 TNNT2 TNNI3 FABP3
8 11.32 VWF FGB F2
9 10.76 F9 F2 F10

GO Terms for Pulmonary Embolism

Cellular components related to Pulmonary Embolism according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.16 VWF SERPINF2 SERPINE1 SERPINC1 PLAT NPPB
2 extracellular exosome GO:0070062 10.14 VWF SERPINF2 SERPINE1 SERPINC1 PLAT FGB
3 extracellular space GO:0005615 10.03 SERPINF2 SERPINE1 SERPINC1 PLAT NPPB FGB
4 endoplasmic reticulum lumen GO:0005788 9.85 SERPINC1 F9 F5 F2 F10 ALB
5 blood microparticle GO:0072562 9.8 SERPINF2 SERPINC1 FGB F2 F13A1 ALB
6 platelet alpha granule GO:0031091 9.61 VWF FGB F5
7 troponin complex GO:0005861 9.52 TNNT2 TNNI3
8 fibrinogen complex GO:0005577 9.51 SERPINF2 FGB
9 platelet alpha granule lumen GO:0031093 9.5 VWF SERPINF2 SERPINE1 FGB F5 F13A1
10 cardiac myofibril GO:0097512 9.49 TNNT2 TNNI3
11 intrinsic component of external side of plasma membrane GO:0031233 9.48 F3 F10
12 cardiac Troponin complex GO:1990584 9.46 TNNT2 TNNI3
13 collagen-containing extracellular matrix GO:0062023 9.36 VWF SERPINF2 SERPINE1 SERPINC1 PLAT FGB

Biological processes related to Pulmonary Embolism according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.85 SERPINC1 F5 F2 ALB
2 ER to Golgi vesicle-mediated transport GO:0006888 9.84 F9 F5 F2 F10
3 platelet degranulation GO:0002576 9.76 VWF SERPINF2 SERPINE1 FGB F5 F13A1
4 blood coagulation, intrinsic pathway GO:0007597 9.67 VWF F9 F2 APOH
5 acute-phase response GO:0006953 9.65 SERPINF2 F2 CRP
6 fibrinolysis GO:0042730 9.65 SERPINF2 SERPINE1 PLAT FGB F2
7 blood coagulation GO:0007596 9.65 VWF SERPINC1 PLAT FGB F9 F5
8 positive regulation of blood coagulation GO:0030194 9.63 SERPINE1 F2 APOH
9 negative regulation of fibrinolysis GO:0051918 9.62 SERPINF2 SERPINE1 F2 APOH
10 regulation of blood coagulation GO:0030193 9.61 SERPINC1 F2 APOH
11 plasminogen activation GO:0031639 9.58 PLAT FGB APOH
12 negative regulation of blood coagulation GO:0030195 9.57 SERPINE1 APOH
13 negative regulation of ATPase activity GO:0032780 9.56 TNNT2 TNNI3
14 blood coagulation, fibrin clot formation GO:0072378 9.52 FGB F13A1
15 negative regulation of plasminogen activation GO:0010757 9.51 SERPINF2 SERPINE1
16 blood coagulation, extrinsic pathway GO:0007598 9.49 F3 F10
17 hemostasis GO:0007599 9.28 VWF SERPINC1 FGB F9 F5 F3

Molecular functions related to Pulmonary Embolism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 VWF TNNT2 TNNI3 SERPINF2 SERPINE1 SERPINC1
2 signaling receptor binding GO:0005102 9.72 SERPINE1 PLAT NPPB FGB F2
3 serine-type peptidase activity GO:0008236 9.56 PLAT F9 F2 F10
4 serine-type endopeptidase activity GO:0004252 9.35 PLAT F9 F3 F2 F10
5 troponin C binding GO:0030172 9.16 TNNT2 TNNI3
6 protease binding GO:0002020 9.02 VWF SERPINF2 SERPINE1 SERPINC1 F3

Sources for Pulmonary Embolism

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....